General Information
Age Group
AdultStatus
ActiveProtocol Number
NCT02816736Background Information
This study seeks to evaluate the effectiveness of sacubatril-valsartan (aka: Entresto) in patients with advanced heart failure.
This is a US, multicenter, placebo-controlled, HFrEF trial. Testing Entresto in patients with any history of NYHA IV symptoms. 26-week study to assess change in NT-proBNP. Sponsor: NIH HF Network.
Offered At
Inova Heart and Vascular Institute
3300 Gallows Road
Falls Church, VA 22042
Principal Investigator
Palak Shah, MD
Eligibility Information
- 18 to 85 years old
- Ejection fraction ≤ 35%
- Advanced HF (any are ok):
- Intropes > 4 days in past 6 months
- 2 or more hospitalizations in 6 months
- EF =< 25%
- eGFR < 45
- 6 minute walk < 300 m
- VO2 < 55% predicted or =< 14 female or =< 16 male
Ineligibility Information
- Age > 85 years
- SBP < 90mmHg
- Scheduled for LVAD within 30 days
- Currently listed for heart transplant (1A or 1B ) and hospitalized
Contact Name
Bhruga Shah
703-776-2995
bhruga.shah@inova.org
or
Vinita Gupta
703-776-3697
vinita.gupta@inova.org
or
Call the main Advanced Heart Failure Research office at 703-776-2828